Entities / Entity
The University of Texas MD Anderson Cancer Center.
hospital in Texas, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 1,655
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
UT MD Anderson Cancer Center and Aprea Therapeutics, Inc. collaborated on translational research, generating preclinical data.Speculative1 report
-
The University of Texas MD Anderson Cancer Center is collaborating with Quest Diagnostics on the development of a new MCaST blood test.Some support1 report
-
FDA granted IND clearance for RV-01 study, which was developed by a joint venture involving Radiopharm Theranostics and based at The University of Texas MD Anderson Cancer Center.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around The University of Texas MD Anderson Cancer Center this week
News at the entities that move The University of Texas MD Anderson Cancer Center most-
Quest Diagnostics OperationalMarket share and investment focus comparison between Quest Diagnostics and GeneDx Holdings Corp. is underway.Moves The University of Texas MD Anderson Cancer Center
Connections
The 1 strongest of 1,655, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Quest Diagnostics Operational
The University of Texas MD Anderson Cancer Center and Quest Diagnostics are collaborating on the development of a cancer risk blood test.
History
Events by the month they beganJune 2026
3 events- UT MD Anderson Cancer Center and Aprea Therapeutics, Inc. collaborated on translational research, generating preclinical data.
- The University of Texas MD Anderson Cancer Center is collaborating with Quest Diagnostics on the development of a new MCaST blood test.
- FDA granted IND clearance for RV-01 study, which was developed by a joint venture involving Radiopharm Theranostics and based at The University of Texas MD Anderson Cancer Center.